Nasal polyps are soft, painless growths on the lining of your nasal passages or sinuses, often resulting from chronic ...

Sinusitis can be acute, lasting less than four weeks, or chronic, lasting longer for months despite treatment. Symptoms of sinusitis include: While sinusitis can be uncomfortable and disruptive, there ...

Treatments for a ... over time or is accompanied by symptoms like shortness of breath and chest pain. Weinberger M, Hurvitz M. Diagnosis and management of chronic cough: similarities and ...

"This could provide a better understanding of the occurrence of chronic cough, which may ultimately result in better treatments for this difficult-to-treat condition." Emilsson and his colleagues ...

[3] CT scans in patients with chronic sinusitis will allow ... a practicing physician for 30 years. Ransom JH. Sinusitis: Diagnosis and Treatment. MedGenMed 1(1), 1999 [formerly published in ...

The data published in The Lancet is being heralded as a big breakthrough in the treatment of cervical cancer and uses readily available chemotherapy drugs, given to patients before they receive ...

This problem, which can be acute or chronic, affects millions of people around the world, making breathing difficult and decreasing quality of life. Below, we'll explore in detail what sinusitis is, ...

(Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis ...

“It’s unlikely that persistent virus is the cause of all long COVID symptoms,” said Dr ... is meaningless unless there’s a follow on treatment,” he said. His new study, he added ...

Department of Otorhinolaryngology Head and Neck Surgery, General Hospital of Ningxia Medical University, Yinchuan, China Objective: To investigate the correlation between chronic rhinosinusitis (CRS .

Depemokimab helped reduce nasal obstruction and polyp size for patients who have chronic rhinosinusitis with nasal polyps, a common condition that GSK said affects up to 4% of the population.

Depemokimab helped reduce nasal obstruction and polyp size for patients who have chronic rhinosinusitis with nasal polyps, a common condition that GSK said affects up to 4% of the population. Of those ...